Search for drugs:
Typing the drug name to query
FENFLURAMINE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dose 4 times the maximum recommended dose, FINTEPLA did not prolong the QT interval when tested in an adult population.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
78
38381509
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- A08AA02 - fenfluramine
- A08AA - Centrally acting antiobesity products
- A08A - "ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS"
- A08 - "ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS"
- A - ALIMENTARY TRACT AND METABOLISM
- N03AX26 - fenfluramine
- N03AX - Other antiepileptics
- N03A - ANTIEPILEPTICS
- N03 - ANTIEPILEPTICS
- N - NERVOUS SYSTEM
Active Ingredient:FENFLURAMINE
Active Ingredient UNII:2DS058H2CF
Drugbank ID:DB00574
PubChem Compound:3337
CTD ID:D005277
PharmGKB:PA449592
CAS Number:458-24-2
Dosage Form(s):solution
Route(s) Of Administrator:oral
Daily Dose:
- 120.0 mg/day A08AA02
Chemical Structure: 
SMILE Code:
CCNC(C)CC1=CC=CC(=C1)C(F)(F)F
CCNC(C)CC1=CC=CC(=C1)C(F)(F)F
Reference
1: Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study.
[Iribarren Carlos,Round Alfred D,Peng Jonathan A,Lu Meng,Zaroff Jonathan G,Holve Taylor J,Prasad Amit,Stang Paul]Pharmacoepidemiol Drug Saf,2013 Nov;22(11):1222-32. PMID: 23857878
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.